{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-010449","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2022-06-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.853071+00:00","generated_at":"2026-06-24T22:17:04.298865+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"low","headline":"Capricor provides top-line update from HOPE-2 open label extension trial","bullets":["Capricor reported top-line results from HOPE-2 OLE (1-year data) via slide presentation on June 27, 2022.","The slide presentation was made available on the company's website; specific data not detailed in the filing.","No numerical results or endpoint data are included in the filed exhibit; only a title slide is reproduced.","The update was disclosed under Regulation FD; a conference call was held the same day."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-010449","json":"https://secwatch.observer/filing/0001558370-22-010449.json","markdown":"https://secwatch.observer/filing/0001558370-22-010449.md","text":"https://secwatch.observer/filing/0001558370-22-010449.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000155837022010449/0001558370-22-010449-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000155837022010449/capr-20220627x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T22:17:04.298865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}